Evidence map›Paper›PMID 41898007›Full record

ReviewBehavioral sciences (Basel, Switzerland)2026

Assessment of Language Impairments Towards Identifying Markers for Early Diagnosis of Pathological Cognitive Decline.

Claudia Espinoza, Diana Martella

Abstract readReview
In one paragraph

Review in Behavioral sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Claudia EspinozaEscuela de Psicología, Facultad de Ciencias Sociales y Comunicación, Universidad Santo Tomas, Valdivia 509000, Chile.ORCID 0009-0000-4337-3980
Diana MartellaDepartamento de Psicología, Facultad de Psicología y Educación, Universidad Loyola de Andalucía, 41007 Sevilla, Spain.ORCID 0000-0003-2565-9728

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A major challenge in research on cognitive decline and dementia is the identification of at-risk populations in the preclinical phase. In this context, there is growing interest in language markers as early indicators of cognitive impairment.

objectivesThis study aims to identify early linguistic markers that may facilitate the detection of individuals at risk of cognitive decline and dementia during the preclinical stage. Additionally, it seeks to evaluate the effectiveness of various assessment techniques and instruments for detecting such language impairments.

methodsA systematic review was conducted in accordance with the PRISMA guidelines, encompassing studies published between 2014 and 2025. A total of 109 articles were included in the qualitative synthesis.

resultsThe findings indicate that syntactic-structural features-particularly complexity, discourse coherence, and global organization-together with acoustic parameters such as pause duration, exhibit a higher accuracy and predictive value for the early diagnosis of cognitive decline and its progression to dementia. Furthermore, narrative-based tasks analyzed through automated methods demonstrate significant advantages for the assessment of language impairments.

conclusionsThe analysis of language markers-particularly through the examination of syntactic complexity, acoustic features, and automated narrative assessments-represents a promising and effective approach for the early identification of cognitive impairment and the prediction of subsequent dementia onset.

Indexed as

assessment techniquescognitive declinecognitive markersdementialanguage impairments

Identifiers

PMID41898007
PMCPMC13024424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.